Today: 1 July 2026
Standard Chartered’s Push Into AI May Cut 7,000 Jobs as Bank Looks for 18% Returns

Standard Chartered’s Push Into AI May Cut 7,000 Jobs as Bank Looks for 18% Returns

Hong Kong, May 19, 2026, 18:02 HKT

Standard Chartered plans to cut over 7,000 jobs by 2030 as it chases a roughly 18% return on tangible equity, with job cuts and artificial intelligence set to drive the next phase for the London lender. Return on tangible equity measures profit against shareholder capital minus intangible assets.

StanChart’s plan is in focus as the bank wraps up a long clean-up and shifts to pushing investors on tougher goals: boosting revenue per employee, cutting costs, and accelerating growth in wealth and institutional banking. The bank said it reached its 2026 medium-term targets a year ahead and now wants RoTE above 15% by 2028 and roughly 18% by 2030.

Chief Executive Bill Winters is set for the update after spending ten years leading a turnaround at the Asia- and Africa-focused lender, steering it away from takeover rumors and returning it to more stable returns. The timing lines up with HSBC’s own investor day this week. HSBC is its bigger rival and has long been a key comparison for investors looking at Asian banks listed in London.

Staff cuts will target corporate functions, mainly support and back-office jobs behind front-line units. According to the Financial Times, affected areas include HR, risk, and compliance across Bengaluru, Tianjin, and Warsaw. The paper said the bank has already hit its $1.5 billion yearly “Fit for Growth” cost-saving goal a year sooner than planned. Financial Times

StanChart wants to boost income per employee by around 20% by 2028 and cut its cost-to-income ratio to about 57% from 63% in 2025. The bank said it plans to use automation, advanced analytics and AI to speed things up, make better decisions and improve client service, as well as make operations run smoother.

The plan’s growth push is focused on wealth and retail banking, with a $200 billion net new money goal by 2028 and affluent clients targeted to bring in 75% of that division’s income. The Wall Street Journal said the bank also predicts high-teens compound annual earnings-per-share growth for 2025-2028, and plans for a dividend payout ratio of at least 30%.

Standard Chartered is moving after posting a strong first quarter. The bank reported record operating income at $5.9 billion, a 9% gain. Profit before tax hit a record $2.5 billion and Wealth Solutions income jumped 32%. The bank also booked a $190 million precautionary overlay linked to the Middle East conflict.

StanChart faces a clear risk. The bank is exposed to markets where shocks can hit trade flows, oil, and credit costs fast. Recent earnings got a lift from wealth inflows and higher rates. “In a world full of uncertainty, performance may prove more challenging further out,” Ed Firth at Keefe, Bruyette & Woods told Reuters. StanChart’s London shares slipped 0.5% in early trade, with analysts calling the targets conservative. Reuters

Standard Chartered named Manus Costello as group CFO, promoting the head of investor relations and ex-equity research executive to the board, pending regulatory sign-off. Tanuj Kapilashrami steps in as group chief operating officer. Winters has been moving to shore up questions about the top team.

StanChart is telling investors it wants to use tech to cut thousands of support roles, move more money and workers to higher-return customers, and show its recent share gains are not just a sign the turnaround is running out of steam. There’s now a further-out target for investors. But there’s also a bigger set of hurdles to clear.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Evolution stock jumps on €2 billion move
Previous Story

Evolution stock jumps on €2 billion move

Constellation Software Stock Climbs as Broader Canadian Market Loses Ground
Next Story

Constellation Software Stock Climbs as Broader Canadian Market Loses Ground

Go toTop